C-type natriuretic peptide analog treatment of craniosynostosis in a Crouzon syndrome mouse model.

C-type natriuretic peptide analog treatment of craniosynostosis in a Crouzon syndrome mouse model.

Activating mutations of fibroblast growth factor receptors (FGFRs) are a major cause of skeletal dysplasias, and thus they are potential targets for pharmaceutical intervention. BMN 111, a C-type natriuretic peptide analog, inhibits FGFR signaling at the level of the RAF1 kinase through natriuretic...

Full description

Bibliographic Details
Main Authors: Greg Holmes, Lening Zhang, Joshua Rivera, Ryan Murphy, Claudia Assouline, Lorraine Sullivan, Todd Oppeneer, Ethylin Wang Jabs
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6062116?pdf=render

Similar Items

Similar Items